title: Oncologic Outcomes of Oral Adjuvant Chemotherapy Regimens in Stage III Colon Cancer: Tegafur-Uracil Plus Leucovorin Versus Capecitabine.
abstract: Although several major trials of treatment for stage III colon cancer have been reported, no study has compared oral adjuvant chemotherapy regimens using tegafur-uracil in combination with leucovorin (UFT/LV) and capecitabine (CAPE) alone. This study compared the oncologic outcomes of treatment with these 2 oral regimens.
  
  
  
  Records of patients with stage III colon cancer who underwent curative surgery and adjuvant chemotherapy from April 2007 and September 2014 were retrospectively reviewed.
  
  
  
  A total of 258 patients with stage III colon cancer received oral adjuvant chemotherapy with UFT/LV (n = 157, 61%) and CAPE (n = 101, 39%). The overall rate of completion of scheduled treatment was 78.6%. Significantly fewer patients on UFT/LV completed the regimen compared with those on CAPE (117, 74.5% vs. 86, 85.1%; P < .01). There were no significant differences in oncologic outcome between UFT/LV and CAPE in terms of 3-year overall survival rates (OS; 95.8% vs. 92.4%, P = .45) and 3-year relapse-free survival rates (RFS; 82.7% vs. 79.3%, P = .8).
  
  
  
  The 3-year RFS and OS were similar for both regimens, yielding an excellent outcome. The selection of adjuvant chemotherapeutic regimens must be based on the patient's status as well as considering the incidences of adverse events, medical cost, and administration convenience.
authors.affiliation: Division of Gastroenterological Surgery, Saitama Medical University International Medical Center, Saitama, Japan. Electronic address: tashiro@saitama-med.ac.jp.
authors.forename: Jo
authors.initials: J
authors.lastname: Tashiro
authors.affiliation: Division of Gastroenterological Surgery, Saitama Medical University International Medical Center, Saitama, Japan.
authors.forename: Shigeki
authors.initials: S
authors.lastname: Yamaguchi
authors.affiliation: Division of Gastroenterological Surgery, Saitama Medical University International Medical Center, Saitama, Japan.
authors.forename: Toshimasa
authors.initials: T
authors.lastname: Ishii
authors.affiliation: Division of Gastroenterological Surgery, Saitama Medical University International Medical Center, Saitama, Japan.
authors.forename: Hiroka
authors.initials: H
authors.lastname: Kondo
authors.affiliation: Division of Gastroenterological Surgery, Saitama Medical University International Medical Center, Saitama, Japan.
authors.forename: Kiyoka
authors.initials: K
authors.lastname: Hara
authors.affiliation: Division of Gastroenterological Surgery, Saitama Medical University International Medical Center, Saitama, Japan.
authors.forename: Hiroki
authors.initials: H
authors.lastname: Shimizu
authors.affiliation: Division of Gastroenterological Surgery, Saitama Medical University International Medical Center, Saitama, Japan.
authors.forename: Kenichi
authors.initials: K
authors.lastname: Takemoto
authors.affiliation: Division of Gastroenterological Surgery, Saitama Medical University International Medical Center, Saitama, Japan.
authors.forename: Asami
authors.initials: A
authors.lastname: Suzuki
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000069287:Capecitabine / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant / Q000379:methods*; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D005641:Tegafur / Q000008:administration & dosage; D016896:Treatment Outcome; D014498:Uracil / Q000008:administration & dosage
chemical_list: D000970:Antineoplastic Agents; D005641:Tegafur; D014498:Uracil; D000069287:Capecitabine; D002955:Leucovorin
keywords: Capecitabine; Oral adjuvant chemotherapy; Stage III colon cancer; Tegafur plus leucovorin; UFT/LV